SUMMARY, EXPLANATION AND LIMITATIONS:
CD5 is a T-cell associated marker that is also expressed by two B-cell neoplasms; lymphocytic leukemia and mantle cell lymphoma. CD5 antigen is expressed in 95% of thymocytes and 72% of peripheral blood lymphocytes. In lymph nodes, CD5 is mainly reactive with T-cells. It has been shown to react with thymic carcinomas, but rarely in thymomas. It has also been observed in a subset of intravascular large B-cell lymphomas and marks some anaplastic large cell lymphomas. CD5 has proven very useful in marking mantle cell lymphoma when used in tandem with CD23, cyclin D1, and CD10 (CD10 is negative; CD5, cyclin D1 are positive for mantle cell lymphoma).
Isotype: IgG1 Kappa
Immunogen: Recombinant fusion protein corresponding to the external domain of Human CD5 molecule.
Staining pattern: Cell membrane.
Positive control: Tissue sample from tonsil.
This antibody is designed for the specific localization of human CD5 using IHC techniques in formalin-fixed, paraffin-embedded tissue sections.